In the era of "national replacement", the pharmaceutical industry should realize localization. China is a huge market for the pharmaceutical industry, but at present, most of my country's pharmaceutical market has been occupied by large foreign companies. In the face of this huge cake, foreign manufacturers are digging for gold, while domestic manufacturers are still struggling.
Under the trend of drug localization, in order to better participate in the market, pharmaceutical companies must pay attention to the competitiveness of their own products, including the cost. Looking ahead, the materials used by pharmaceutical companies in the drug R&D and production process are still keen on imported products with higher prices than domestic brands. This may have something to do with the common thinking of the Chinese that the quality of domestic products is worse than that of imported products. But friends, we are fortunate to be at a stage where we are experiencing the rising and then rising capabilities of all aspects of the country. At this time when the overall national strength is far ahead, domestic brands are not inferior to imports, or even better.
As Professor Li Ling from the China Center for Economic Research of Peking University said: "The pharmaceutical industry should be fully localized. The medical and health industry not only undertakes the task of creating a healthy nation, it can also become a profit-creating "golden industry." The localization of the pharmaceutical industry There is no precedent in the world. India’s experience in this area can give China some enlightenment. China’s pharmaceutical industry should follow India’s example and implement full localization."